Emerging Biotechs Adopt Veeva Basics to Accelerate Drug Development

For startups like Whitehawk Therapeutics, which employs fewer than 40 people, the shift away from paper-based systems is critical to maintaining momentum in developing antibody-drug conjugates. Bryan Ball, the company’s chief technology operations officer, noted that the platform enables high-growth teams to manage complex regulatory and quality workflows with minimal overhead. By removing the need for extensive IT support, these companies can focus resources on the science of drug discovery rather than administrative hurdles.

Beyond general operational efficiency, the software is altering how firms manage submissions to health authorities. Structure Therapeutics, for instance, has moved its regulatory publishing in-house using Veeva Submissions Publishing Basics. According to Darryl Clarke, global head of regulatory operations, this shift provides tighter quality control and faster timelines compared to traditional outsourcing models. Built on the Vault Platform, these tools are designed to provide the flexibility required for biotechs to hit critical milestones while maintaining the ability to expand their systems as their product pipelines advance.